199 results on '"Zeng, Qing-Lei"'
Search Results
2. Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
3. LiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population
4. Development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis B patients with concurrent hepatic steatosis: a cohort study
5. Machine Learning–Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis
6. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study
7. Anti-HBV Drugs in Liver Cirrhosis
8. TOP-006 Development and validation of a home-based score to detect advanced liver fibrosis and long-term liver-related outcomes in the general population: a multicohort study
9. WED-272 A self-testing index for detecting hepatic steatosis and prognostication in the general population
10. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
11. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study
12. Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients
13. Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study.
14. Sex disparities of the effect of the COVID-19 pandemic on mortality among patients living with tuberculosis in the United States
15. Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
16. Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study
17. Carvedilol to prevent decompensation of liver cirrhosis in patients with clinically significant portal hypertension stratified by novel non-invasive model
18. Pyroptotic MAITs link microbial translocation with severity of alcohol-related liver disease
19. Eight weeks or less of tenofovir alafenamide to prevent the perinatal hepatitis B transmission: a multicenter, prospective, randomized study
20. Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with non-alcoholic fatty liver disease (NAFLD)
21. Establishment and validation of a diagnostic model for liver inflammation in chronic hepatitis B (CHB) patients concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
22. A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)
23. Pyroptotic MAITs link microbial translocation with severity of alcohol-associated liver disease
24. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors
25. TOP-078 - Pyroptotic MAITs link microbial translocation with severity of alcohol-related liver disease
26. Safety and immunogenicity of COVID‐19 vaccination in patients with hepatocellular carcinoma (CHESS‐NMCID 2101): A multicenter prospective study
27. ABC: a novel algorithm to stratify decompensation risk in patients with cACLD (CHESS2102): an international, multicenter cohort study
28. Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study
29. Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C
30. Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China
31. Computed Tomography Images of Spontaneous Portosystemic Shunt in Liver Cirrhosis
32. Sofosbuvir‐based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study
33. The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
34. Additional file 2 of Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients
35. Additional file 1 of Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients
36. AMPK activation ameliorates D-GalN/LPS-induced acute liver failure by upregulating Foxo3A to induce autophagy
37. ABC: A Novel Algorithm to Stratify Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease: an International, Multicenter Cohort Study
38. A Novel Model for the Screening of Varices in Patients With Compensated Cirrhosis: An International Multicenter Study
39. HCV-specific interleukin-21+CD4+ T cells responses associated with viral control through the modulation of HCV-specific CD8+ T cells function in chronic hepatitis C patients
40. Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells
41. Interferon-α plus ribavirin therapy yields 98% sustained virologic response in children aged 1-5 years with unsafe injection-acquired chronic hepatitis C: 47
42. Clinical Features of Imported Chinese COVID-19 Patients Following Chinese Inactivated Vaccines Injection Abroad
43. HBsAg Loss Due to Tenofovir Treatment for HBV Reactivation Following DAAs Therapy in One Patient with HBV-HCV Coinfection
44. Genomic Epidemiology of SARS-CoV-2 From Mainland China With Newly Obtained Genomes From Henan Province
45. Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccinees
46. Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort
47. Ionic liquid extraction of silkworm pupa protein and its biological characteristics
48. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study
49. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
50. WED-122 - Eight weeks or less of tenofovir alafenamide to prevent the perinatal hepatitis B transmission: a multicenter, prospective, randomized study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.